



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

110

Applicant(s): Armistead et al.

Serial No.: 09/685,053

Group Art Unit No.: 1624

Filed: October 6, 2000

Examiner: Balasubramanian, V.

For: Kinase Inhibitors

Docket No.: A-748E

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant, by the undersigned attorney/agent, certifies that no information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than [30 days pursuant to 37 C.F.R. 1.704(d) or] three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Joseph W. Bulock
Attorney/Agent for Applicant(s)
Registration No.: 37,103
Phone: (805) 447-7966
Date: February 5, 2003

Please send all future correspondence to:
U.S. Patent Operations/ JWBcb
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799